Genome sequencing and gene expression analyses of prostate tumours have highlighted
the potential importance of genetic and epigenetic changes observed in WNT signalling …

Metastatic biopsy programmes combined with advances in genomic sequencing have
provided new insights into the molecular landscape of castration-resistant prostate cancer …

The level of SETD2-mediated H3K36me3 is inversely correlated with that of EZH2-catalyzed
H3K27me3. Nevertheless, it remains unclear whether these two enzymatic activities are …

Prostate cancer is a hormone-dependent malignancy, whose onset and progression are
closely related to the activity of the androgen receptor (AR) signaling pathway. Due to this …

Current treatments for castration-resistant prostate cancer (CRPC) that target androgen
receptor (AR) signaling improve patient survival, yet ultimately fail. Here, we provide novel …

A significant fraction of patients with advanced prostate cancer treated with androgen
deprivation therapy experience relapse with relentless progression to lethal metastatic …

We report the discovery of ARD-2051 as a potent and orally efficacious androgen receptor
(AR) proteolysis-targeting chimera degrader. ARD-2051 achieves DC50 values of 0.6 nM …

Background Hormonal therapy targeting the androgen receptor inhibits prostate cancer
(PCa), but the tumor eventually recurs as castration-resistant prostate cancer (CRPC) …

Many diseases, including cancer, stem from aberrant activation or overexpression of
oncoproteins that are associated with multiple signaling pathways. Although proteins with …

Purpose: Neuroendocrine prostate cancer (NEPC) is an aggressive variant of prostate
cancer that may develop de novo or as a mechanism of treatment resistance. N-myc is …